How should cytokine release syndrome be managed, including anti‑IL‑6 therapy, corticosteroids, and supportive care?

Management of Cytokine Release Syndrome

For cytokine release syndrome, initiate tocilizumab 8 mg/kg IV (maximum 800 mg) at grade 2 severity, escalate to dexamethasone 10 mg IV every 6 hours for grade 3, and use high-dose methylprednisolone 500 mg IV every 12 hours for grade 4 or refractory cases, while providing aggressive supportive care throughout. 1

Grading-Based Treatment Algorithm

Grade 1 CRS (Fever ≥38°C only, no hypotension or hypoxia)

• Provide supportive care with antipyretics, IV hydration, and symptomatic management 1
• Obtain blood cultures and consider empiric broad-spectrum antibiotics if neutropenic 1
• Monitor closely but do not initiate tocilizumab or corticosteroids 1
• If fever persists beyond 3 days, escalate management to grade 2 protocols 1

Grade 2 CRS (Fever + hypotension not requiring vasopressors OR hypoxia requiring ≤6 L/min oxygen)

• Continue supportive care with IV fluid boluses and supplemental oxygen as needed 1
• Administer tocilizumab 8 mg/kg IV over 1 hour (maximum 800 mg per dose) 1
• Repeat tocilizumab every 8 hours if no improvement, limiting to maximum 3 doses in 24 hours and 4 doses total 1
• In children <30 kg, use tocilizumab 12 mg/kg 1
• If hypotension persists after two fluid boluses and 1-2 doses of tocilizumab, add dexamethasone 10 mg IV every 12 hours for 1-2 doses 1
• Alert ICU and consider transfer, especially in centers with limited CAR T-cell experience 1

Grade 3 CRS (Fever + hypotension requiring vasopressor OR high-flow oxygen/non-rebreather mask)

• Transfer to ICU immediately 1
• Administer tocilizumab as per grade 2 if maximum dose not reached 1
• Initiate dexamethasone 10 mg IV every 6 hours concurrently with tocilizumab 1
• Rapidly taper corticosteroids once symptoms improve 1
• Obtain echocardiogram to assess cardiac function and conduct hemodynamic monitoring 1
• If no improvement within 3 days and alternative diagnoses excluded, consider repeating tocilizumab 1

Grade 4 CRS (Fever + multiple vasopressors OR positive pressure ventilation)

• Continue all grade 3 interventions plus mechanical ventilation as needed 1
• Escalate to high-dose methylprednisolone 500 mg IV every 12 hours for 3 days 1
• Follow with methylprednisolone taper: 250 mg IV every 12 hours for 2 days, then 125 mg every 12 hours for 2 days, then 60 mg every 12 hours until improvement to grade 1 1
• Alternative regimen: methylprednisolone 1000 mg/day for 3 days, then 250 mg twice daily for 2 days, 125 mg twice daily for 2 days, 60 mg twice daily for 2 days 1
• If still not improving, consider methylprednisolone 1000 mg IV twice daily or alternate therapies 1

Critical Management Principles

Tocilizumab Administration

• IL-6 blockade with tocilizumab is the cornerstone of CRS treatment and does not compromise CAR T-cell efficacy 2, 3
• Earlier tocilizumab administration (within 24 hours of fever onset) may prevent progression to severe CRS requiring glucocorticoids, though patients with rapid fever onset often need multiple doses 4
• Maximum of 4 total doses of tocilizumab should be administered 1
• Tocilizumab does not cross the blood-brain barrier, making it ineffective for neurological complications 2

Corticosteroid Use

• Reserve corticosteroids for grade 3 or higher CRS, or grade 2 refractory to tocilizumab 1
• Earlier steroid use reduces CRS severity but raises concerns about attenuating antitumor activity, though this appears less problematic with modern protocols 1, 4
• Corticosteroids suppress T-cell activity and should be used judiciously 2
• Strongly consider antifungal prophylaxis in all patients receiving corticosteroids for CRS 1

Infection Considerations

• CRS mimics sepsis clinically, making differentiation challenging 5
• Infections occur in up to 23% of patients post-CAR T therapy, with pathogens including gram-positive/negative bacteria, herpesviruses (CMV, HSV), fungi (Candida, Aspergillus), and parasites 5
• Obtain blood cultures and initiate empiric broad-spectrum antibiotics early, especially in neutropenic patients 1
• Immunosuppressive therapy for CRS further elevates infection risk, requiring vigilant monitoring 5

Common Pitfalls and Caveats

• Do not use GM-CSF (granulocyte-macrophage colony-stimulating factor) as it may worsen CRS 1
• Fever is not required to grade CRS severity once antipyretics or anticytokine therapy has been administered; subsequent grading is driven by hypotension and hypoxia 1
• Organ toxicities (cardiac, hepatic, renal dysfunction) may accompany CRS but do not influence CRS grading itself 1
• Routine anti-convulsant prophylaxis is not recommended except in high-risk cases 1
• Delay CAR T-cell infusion until active infections or uncontrolled hypotension are resolved 1

Emerging and Alternative Therapies

For refractory cases unresponsive to tocilizumab and corticosteroids, alternative agents with limited experience include anakinra (IL-1 receptor antagonist), siltuximab (anti-IL-6 antibody), ruxolitinib (JAK inhibitor), cyclophosphamide, and antithymocyte globulin 1, 6